eltrekibart (LY3041658) / Eli Lilly - LARVOL DELTA

Eltrekibart: Primary completion of P2 trial (NCT06046729) for adult participants with moderate to severe hidradenitis suppurativa in Aug 2025 (Eli Lilly) - Q4 2024 Results: Completion of P2 trial for adult participants with moderate to severe hidradenitis suppurativa in Jul 2026

Trial completion date • Trial primary completion date • Hidradenitis Suppurativa

A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis (clinicaltrials.gov) - P2 | N=140 | Recruiting | Sponsor: Eli Lilly and Company | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis (clinicaltrials.gov) - P2 | N=140 | Not yet recruiting | Sponsor: Eli Lilly and Company

Combination therapy • New P2 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Eltrekibart: Primaty completion of P2 trial (NCT06046729) adult participants with moderate to severe hidradenitis suppurativa in Aug 2025 (Eli Lilly) - Q2 2024 Results: Completion of P2 trial (NCT06046729) adult participants with moderate to severe hidradenitis suppurativa in Jul 2026

Trial completion date • Trial primary completion date • Hidradenitis Suppurativa

A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa (clinicaltrials.gov) - P2 | N=350 | Recruiting | Sponsor: Eli Lilly and Company | Trial completion date: Mar 2026 ➔ Jul 2026 | Trial primary completion date: Apr 2025 ➔ Aug 2025

Trial completion date • Trial primary completion date • Dermatology • Hidradenitis Suppurativa • Immunology

An Update on Current Clinical Management and Emerging Treatments in Hidradenitis Suppurativa. (PubMed, Skin Therapy Lett) - "However, HS is often refractory to traditional treatments, prompting the need for newer and more effective therapies. Herein, we review current and emerging HS therapies."

Journal • Dermatology • Hidradenitis Suppurativa • Immunology • Inflammation • Pain

A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa (clinicaltrials.gov) - P2 | N=350 | Recruiting | Sponsor: Eli Lilly and Company | Phase classification: P2b ➔ P2 | Trial completion date: Jul 2026 ➔ Mar 2026 | Trial primary completion date: Jul 2025 ➔ Apr 2025

Phase classification • Trial completion date • Trial primary completion date • Dermatology • Hidradenitis Suppurativa • Immunology

A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa (clinicaltrials.gov) - P2b | N=350 | Recruiting | Sponsor: Eli Lilly and Company | Not yet recruiting ➔ Recruiting

Enrollment open • Dermatology • Hidradenitis Suppurativa • Immunology

Safety and Efficacy of LY3041658, a Novel Septa-Specific Monoclonal Antibody to CXCR1 and CXCR2 Ligands, in a Phase 2 Study in Hidradenitis Suppurativa (EADV 2023) - P2 | "Overall, neutralizing seven distinct CXCR1/CXCR2 ligands with a septa-specific monoclonal antibody is a promising therapeutic strategy for HS and potentially other neutrophil-predominant disorders. Previously presented at American Academy of Dermatology - 81st Annual Meeting 2023"

Clinical • P2 data • Dermatology • Hidradenitis Suppurativa • Immunology • Infectious Disease • Inflammation • CXCR1 • CXCR2

A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa (clinicaltrials.gov) - P2b | N=350 | Not yet recruiting | Sponsor: Eli Lilly and Company

New P2b trial • Dermatology • Hidradenitis Suppurativa • Immunology

Safety and Efficacy of LY3041658, a Novel Septa-Specific Monoclonal Antibody to CXCR1 and CXCR2 Ligands, in a Phase 2 Study in Hidradenitis Suppurativa (AAD 2023) - No abstract available

Clinical • Late-breaking abstract • P2 data • Dermatology • Hidradenitis Suppurativa • CXCR1 • CXCR2

A Study of LY3041658 in Adults With Hidradenitis Suppurativa (clinicaltrials.gov) - P2 | N=72 | Completed | Sponsor: Eli Lilly and Company | Active, not recruiting ➔ Completed | N=52 ➔ 72

Enrollment change • Trial completion • Dermatology • Hidradenitis Suppurativa

LY3041658/ interleukin-8 complex structure as targets for IL-8 small molecule inhibitors discovery using a combination of in silico methods. (PubMed, SAR QSAR Environ Res) - "Furthermore, the MM/PBSA technique has been utilized to evaluate the free binding energy. The final data confirmed that one newly obtained compound, ZINC21882765, may serve as the best potential inhibitor for IL-8."

Journal • Immunology • Infectious Disease • Novel Coronavirus Disease • Oncology • CXCL8 • CXCR1 • CXCR2

A Study of LY3041658 in Adults With Hidradenitis Suppurativa (clinicaltrials.gov) - P2 | N=52 | Active, not recruiting | Sponsor: Eli Lilly and Company | Recruiting ➔ Active, not recruiting

Enrollment closed • Dermatology • Hidradenitis Suppurativa

A Study of LY3041658 in Adults With Hidradenitis Suppurativa (clinicaltrials.gov) - P2; N=52; Recruiting; Sponsor: Eli Lilly and Company; Trial completion date: Jul 2022 ➔ Dec 2022; Trial primary completion date: Dec 2021 ➔ Apr 2022

Clinical • Trial completion date • Trial primary completion date • Dermatology • Hidradenitis Suppurativa

A Study of LY3041658 in Healthy Participants (clinicaltrials.gov) - P1; N=16; Completed; Sponsor: Eli Lilly and Company; Active, not recruiting ➔ Completed

Trial completion

A Study of LY3041658 in Healthy Participants (clinicaltrials.gov) - P1; N=16; Active, not recruiting; Sponsor: Eli Lilly and Company; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed

A Study of LY3041658 in Healthy Participants (clinicaltrials.gov) - P1; N=16; Recruiting; Sponsor: Eli Lilly and Company; Suspended ➔ Recruiting

Clinical • Enrollment open

A Study of LY3041658 in Healthy Participants (clinicaltrials.gov) - P1; N=16; Suspended; Sponsor: Eli Lilly and Company; Recruiting ➔ Suspended

Clinical • Trial suspension

A Study of LY3041658 in Healthy Participants (clinicaltrials.gov) - P1; N=16; Recruiting; Sponsor: Eli Lilly and Company; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open

A Study of LY3041658 in Healthy Participants (clinicaltrials.gov) - P1; N=16; Not yet recruiting; Sponsor: Eli Lilly and Company

Clinical • New P1 trial

Discovery and characterization of a neutralizing pan-ELR+CXC chemokine monoclonal antibody. (PubMed, MAbs) - "In addition to the in vitro and in vivo activity, we characterized the epitope and structural basis for binding in detail through alanine scanning, crystallography, and mutagenesis. Together, these data provide a robust preclinical characterization of LY3041658 for which the efficacy and safety is being evaluated in human clinical trials for neutrophilic skin diseases."

Journal • Dermatology • Oncology • CXCR1 • CXCR2

A Study of LY3041658 in Adults With Hidradenitis Suppurativa (clinicaltrials.gov) - P2; N=52; Recruiting; Sponsor: Eli Lilly and Company; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Dermatology • Hidradenitis Suppurativa

A Study of LY3041658 in Adults With Hidradenitis Suppurativa (clinicaltrials.gov) - P2; N=52; Not yet recruiting; Sponsor: Eli Lilly and Company

Clinical • New P2 trial • Dermatology • Dermatopathology • Hidradenitis Suppurativa

A Study of LY3041658 in Participants With Skin Diseases (clinicaltrials.gov) - P1; N=60; Completed; Sponsor: Eli Lilly and Company; Active, not recruiting ➔ Completed

Trial completion